Nuclear factor erythroid 2-related factor 2 (NRF2) is a redox-activated transcription factor regulating cellular defense against oxidative stress, thereby playing a pivotal role in maintaining cellular homeostasis. Its dysregulation is implicated in the progression of a wide array of human diseases, making NRF2 a compelling target for therapeutic interventions. However, challenges persist in drug discovery and safe targeting of NRF2, as unresolved questions remain especially regarding its context-specific role in diseases and off-target effects. This comprehensive review discusses the dualistic role of NRF2 in disease pathophysiology, covering its protective and/or destructive roles in autoimmune, respiratory, cardiovascular, and metabolic diseases, as well as diseases of the digestive system and cancer. Additionally, we also review the development of drugs that either activate or inhibit NRF2, discuss main barriers in translating NRF2-based therapies from bench to bedside, and consider the ways to monitor NRF2 activation in vivo.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.redox.2025.103569 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Microbiome in Asthma Heterogeneity: The Role of Multi-Omic Investigations.
Immunol Rev
March 2025
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Asthma is one of the most prevalent and extensively studied chronic respiratory conditions, yet the heterogeneity of asthma remains biologically puzzling. Established factors like exogenous exposures and treatment adherence contribute to variability in asthma risk and clinical outcomes. It is also clear that the endogenous factors of genetics and immune system response patterns play key roles in asthma.
View Article and Find Full Text PDFMolecular insights into the antineoplastic potential of apigenin and its derivatives: paving the way for nanotherapeutic innovations.
Expert Opin Drug Deliv
March 2025
Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.
Introduction: Apigenin, a widely distributed bioactive flavonoid, has recently gained excellent attention among researchers as an effective anticancer drug that can alternate cancer signaling pathways, induce programmed cell death, and reduce tumor growth in various cancer types. Despite its impressive anti-neoplastic activity, high hydrophobicity and nonspecific biodistribution make apigenin difficult for pharmaceutical application.
Areas Covered: We highlighted the therapeutic potential of apigenin and its derivatives in different cancer types, along with their mechanism of action.
Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases.
Redox Biol
March 2025
A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland. Electronic address:
Nuclear factor erythroid 2-related factor 2 (NRF2) is a redox-activated transcription factor regulating cellular defense against oxidative stress, thereby playing a pivotal role in maintaining cellular homeostasis. Its dysregulation is implicated in the progression of a wide array of human diseases, making NRF2 a compelling target for therapeutic interventions. However, challenges persist in drug discovery and safe targeting of NRF2, as unresolved questions remain especially regarding its context-specific role in diseases and off-target effects.
View Article and Find Full Text PDFPreserving potential: Surgeons as key partners in establishing a living sarcoma biobank for translational research purposes.
Surg Oncol
March 2025
Cancer Research Institute Ghent, Ghent University, Ghent, Belgium; Department of Orthopaedics and Traumatology, Ghent University Hospital, Ghent, Belgium. Electronic address:
Background: Sarcoma is a rare type of cancer, of which over 70 distinct molecular subtypes are known. Because these tumours are so rare and complex, treatment outcomes have remained similar over the past decades and research is progressing slowly. For these rare cancers, personalised medicine and patient-derived models might pose solutions for therapeutic problems, but researchers depend on clinicians to access fresh, viable tumour tissue.
View Article and Find Full Text PDFA bench-to-bedside narrative review of the sleep-social-oxytocin nexus.
Sleep Med Rev
February 2025
The University of Sydney, Faculty of Science, School of Psychology, Sydney, New South Wales, Australia; The University of Sydney, Brain and Mind Centre, Sydney, New South Wales, Australia. Electronic address:
Although recognition of the significant reciprocal interplay between sleep and social processes has grown over the past two decades, theoretical frameworks conceptualising this interplay have predominantly focused on psychosocial factors. The current lack of attention to putative neurobiological substrates and physiological mechanisms that may facilitate the dynamics of sleep-social relationships limits interdisciplinary research into sleep and clinical treatment of sleep problems and disorders. Thus, this narrative review hypothesises that the neuropeptide oxytocin represents a promising candidate physiological substrate underpinning sleep-social interplay, and integrates the endogenous oxytocin system into a novel tripartite biopsychosocial framework-the sleep-social-oxytocin nexus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!